Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

157.38 +2.64 (+1.71%)
Streaming Delayed Price Updated: 11:26 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,436
Open 156.12
Bid (Size) 157.11 (4)
Ask (Size) 157.71 (4)
Prev. Close 154.74
Today's Range 155.30 - 158.39
52wk Range 126.97 - 225.23
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
From BeiGene, Ltd.
Via Business Wire

Performance

YTD
-11.08%
-11.08%
1 Month
+0.82%
+0.82%
3 Month
+20.20%
+20.20%
6 Month
+0.49%
+0.49%
1 Year
-19.39%
-19.39%

More News

Read More
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
Via Benzinga
Evaluating BeiGene: Insights From 6 Financial Analysts
Via Benzinga
4 Analysts Assess BeiGene: What You Need To Know
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Via Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Via Talk Markets
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
7 Large-Cap Stocks That Can Jump 50% By 2025
Via InvestorPlace
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
Via Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
From BeiGene, Ltd.
Via Business Wire
BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Via Benzinga
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
From BeiGene, Ltd.
Via Business Wire
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Via Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.